ClinicalTrials.gg

Program

MIF Inhibitor IPG1094

Also written as “IPG1094 Tablets”, “IPG1094 300 mg SAD” and “IPG1094 600 mg SAD”.

Its studies are led by Nanjing Immunophage Biotech.

Furthest: phase 2, since Dec 25, 20233 company-led studies, 2 open or runningNext primary completion: Jan 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Immunophage Biotech32 open or runningphase 2since Dec 25, 2023Sep 16, 2021Jan 30, 2027phase 1 · NCT07679113

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 16, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05112159 · 76 enrolled · Australia
  2. Dec 25, 2023Phase 2 study in Solid TumorNCT06212076 · 60 planned · China
  3. Jun 25, 2026Phase 1 study in Healthy VolunteersNCT07679113 · 24 planned · China

Ahead

  1. Jan 30, 2027Primary completion: phase 1 study in Healthy VolunteersNCT07679113
  2. Jul 9, 2027Primary completion: phase 2 study in Solid TumorNCT06212076

TargetBeta

MIF →read by rule
“An orally bioavailable inhibitor of the pro-inflammatory cytokine macrophage migration inhibitory factor (MIF), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07679113Healthy Volunteers · China1RecruitingJan 30, 202724
NCT06212076Solid Tumor · China2RecruitingJul 9, 202760
NCT05112159Healthy Volunteers · Australia1CompletedJul 25, 202276

How it is read

Names in the registry

  • “IPG1094 Tablets”, 1 entry
  • “IPG1094 300 mg SAD”, 1 entry
  • “IPG1094 600 mg SAD”, 1 entry
  • “IPG1094 900 mg SAD”, 1 entry
  • “IPG1094 1200 mg SAD”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.